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Fetal Programming of Adult
Cardiovascular Disease
It is now accepted that the risk of car-
diovascular disease (CVD), which is a
leading cause of death in the twenty-first
century, is influenced by the interaction
between our genes and environment.
Subclinical CVD begins to evolve early in
life, long before the clinical symptoms
appear decades later and strong evidence
supports that it may start before birth.1-3
The best characterized prenatal risk
factor for CVD is fetal growth restriction
(FGR). Epidemiologic studies that have
been published in the past four decades,
first demonstrated that low birthweight
was associated with an increased risk of
death from coronary heart disease,4-12
stroke,5,10 hypertension,13-16 impaired
glucose tolerance, and noneinsulin-
dependent diabetes mellitus.15,17,18
These associations have been described
beyond disparities in life expectancy or
healthcare system.10,19 The phenome-
non to explain this relationship was
denominated fetal programming.20,21
Structural, functional, and metabolic
changes that occur in the fetus as an
adaptive response to an adverse or
suboptimal environment persist into
postnatal life, which leads to a greater
risk of disease in adulthood.20,22 In
relation with CVDs, fetal programming
is thought to occur through two main
pathways: metabolic programming and
cardiovascular remodeling.
Metabolic programming was the first
hypothesis to explain the association of
CVDs with low birthweight.23-25
Nutrient restriction during a period of
intense epigenetic programming, such as
fetal life, would promote developmental
pathways that best suit this environment,
through the selection of “thrifty genes”
(or molecular pathways).1,23,26,27
Because in postnatal life nutrient avail-
ability will be normal, this programming
will facilitate a higher incidence of
metabolic disease, which includes
obesity, diabetes mellitus, and metabolic
syndrome, which secondarily may lead
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In the modern world, cardiovascular disease is a leading cause of death for both men and
women. Epidemiologic studies consistently have suggested an association between low
birthweight and/or fetal growth restriction and increased cardiovascular mortality rate in
adulthood. Furthermore, experimental and clinical studies have demonstrated that
sustained nutrient and oxygen restriction that are associated with fetal growth restriction
activate adaptive cardiovascular changes that might explain this association. Fetal
growth restriction results in metabolic programming that may increase the risk of
metabolic syndrome and, consequently, of cardiovascular morbidity in the adult. In
addition, fetal growth restriction is strongly associated with fetal cardiac and arterial
remodeling and a subclinical state of cardiovascular dysfunction. The cardiovascular
effects ocurring in fetal life, includes cardiac morphology changes, subclinical
myocardial dysfunction, arterial remodeling, and impaired endothelial function, persist
into childhood and adolescence. Importantly, these changes have been described in all
clinical presentations of fetal growth restriction, from severe early- to milder late-onset
forms. In this review we summarize the current evidence on the cardiovascular effects of
fetal growth restriction, from subcellular to organ structure and function as well as from
fetal to early postnatal life. Future research needs to elucidate whether and how early life
cardiovascular remodeling persists into adulthood and determines the increased car-
diovascular mortality rate described in epidemiologic studies.
Key words: cardiovascular disease, echocardiography, epigenetics, fetal growth
restriction and fetal programming
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to CVDs.26,28 Compelling experimental
evidence supports the effects of nutrient
restriction on epigenetic metabolic
pathways in the offspring after FGR.29,30
Likewise, postnatal follow-up studies of
children with FGR have reported the
influence of postnatal nutrition and
catch-up in the risk of metabolic syn-
drome and obesity.31-33 However, post-
natal obesity, diabetes mellitus, or
metabolic syndrome affect, in a highly
heterogeneous manner, subjects who
were born with a low birthweight and
these conditions are actually uncommon
in some reported cohorts.34,35 Conse-
quently, although metabolic program-
ming must be a contributing factor, it
cannot explain per se the epidemiologic
association between FGR and CVDs.36
Over the last 10 years, a second
important line of evidence has shown
that FGR is also associated with direct
changes in the cardiovascular system.37
Because these changes persist into
childhood and early adulthood, primary
cardiovascular programming and remod-
eling can also be an important link to
explain the association between FGR and
adult CVDs.38 However, cardiovascular
remodeling leads to subclinical changes
in cardiac and vascular structure and
function. Therefore, as with metabolic
programming, it remains to be estab-
lished how these changes combine with
other prenatal or postnatal factors to
lead to clinical CVD in adulthood. In this
review, we will focus on the evidence that
supports fetal cardiovascular remodeling
in FGR; we will discuss potential path-
ways for its association with clinical
CVDs in adults, and the potential
implications for preventive public health
strategies and treatments that could have
a strong impact in the reduction of
CVDs. Table 1 is a glossary containing
terms used in this review that might be






FGR, defined as a failure to achieve the
genetic growth potential, affects 7e10%
of pregnancies.39 In the majority of
cases, fetal smallness is the consequence
of placental insufficiency. FGR has two
main clinical presentations according to
the gestational age of appearance, early
and late onset, which are discussed in
detail elsewhere.40-43 By arbitrary
convention, late-onset small fetuses are
usually subclassified into late-onset FGR
(birthweight <3rd percentile or
abnormal fetoplacental and uterine
Doppler findings) or small for gesta-
tional age (SGA; birthweight 3rd - 9th
percentile and normal Doppler find-
ings).44-47 Although they differ in
severity, clinical features,48-52 and peri-
natal outcomes,40,52-54 all the afore-




2-Dimensional speckle tracking echocardiography Imaging technique that analyzes the magnitude of myocardial deformation in different
directions by the use of the naturally occurring speckle pattern in the myocardium.
Cardiomyocite Columnar-shaped cells 20 mm in diameter and 60e140 mm in length that make up the
cardiac muscle.
Epigenetics The study of the chemical modification of specific genes or gene-associated proteins of
an organism.
Epigenome Record of the chemical changes to the DNA and histone proteins of an organism.
Hypertrophy The enlargement or overgrowth of an organ or part because of an increase in size of its
constituent cells.
Intima-media thickness Measurement of the thickness of tunica intima and tunica media, the innermost 2 layers
of the wall of an artery.
M-mode echocardiography One-dimensional analysis of the heart in motion. It provides both high spatial and
temporal resolution and usually is used to measure the thickness of the ventricular walls
and the volumes of the cardiac chambers.
Myocardial performance index (Tei index) Doppler-derived index of combined systolic and diastolic function. Defined as the sum of
isovolumic contraction time and isovolumic relaxation time divided by the ejection time.
Myocardial strain Percentage of change in the length of a myocardial segment during a given period of
time.
Sarcomere Fundamental contractile unit within the cardiomyocyte, defined as the segment between
2 neighboring Z-lines (or Z-discs, or Z bodies).
Tissue Doppler imaging Echocardiographic technique that uses Doppler effect principles to quantify the
myocardial tissue motion.
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FGR or SGA) have been reported to be
associated with cardiovascular pro-
gramming and remodeling.55-58
Placental insufficiency has two direct
effects on fetal cardiovascular develop-
ment. First, reduced oxygen and nutri-
ents supply may disrupt cardiomyocyte
growth and fiber architecture; and
second, villous hypoplasia/thrombosis
leads to increased placental resistance
and chronic cardiac afterload. Conse-
quently, the developing myocardium
develops a variety of changes in cardiac
macro and microstructure and function,
which is defined as cardiac remodeling, to
maintain ventricular output (Figure 1).59
Initially, the heart develops a more
spherical shape that allows maintaining
stroke volume with less contraction
force, while also reducing wall stress to
better tolerate pressure overload.60
This may happen in one ventricle
(“elongated” phenotype, where a glob-
ular right ventricle pushes the septum
and elongates the left ventricle) or both
ventricles (“globular” phenotype). In
more severe and/or prolonged cases,
increased sphericity may not be enough,
then hypertrophy develops to increase
contractility and decrease local wall
stress. Thus, cardiomegaly is a charac-
teristic change, with three different
phenotypes (elongated, globular, and
hypertrophic) suggesting a progression
of severity.60 Early-onset FGR is more
associated with a hypertrophic response,
whereas cardiac phenotypes late-onset
FGR usually develops globular or
elongated.60 Evaluation of cardiac
morphometric parameters, such as the
sphericity index, might be more stable
and reproducible compared with func-
tional parameters (eg, more susceptible

















Fetal cardiovascular programming and remodeling associated to fetal growth restriction
Sustained restriction of nutrients and oxygen is associated with cardiovascular remodeling at organ, tissue, and subcellular levels (right upper panel)
and with epigenetic changes (mid left panel). Different fetal cardiac phenotypes eelongated, globular and hypertrophic (lower panel)emay be
observed by cardiac imaging, depending on the severity/duration of the insult. Other abnormalities not included in this Figure (such as hypertension,
endothelial dysfunction, and insulin resistance) can operate simultaneously.
miRNA, microRNA.
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Alterations in cardiac shape are
accompanied by subclinical cardiac
dysfunction.39 Both can be demon-
strated with fetal echocardiography.61,62
M-mode and tissue Doppler imaging
show reduced longitudinal myocardial
motion (reduced tricuspid and mitral
annular excursion [tricuspid annular
plane systolic excursion/mitral annular
plane systolic excursion] and annular
peak velocities), which reflects subclini-
cal systolic dysfunction.58-60 Likewise,
diastolic dysfunction appears from early
stages63-67 as increased pulsatility in
ductus venosus,49,68,69 abnormal trans-
mitral E/A ratios (a marker of left
ventricular function that reflects early
ventricular filling [the E wave] and late
diastolic filling caused by atrial contrac-
tion [the A wave]),49,66,69 prolonged
isovolumic relaxation time and
myocardial performance index (Tei
index),66 and decreased diastolic annular
peak velocities (E’ and A’).39,63,65,66,69-73
Additionally, 2-dimensional speckle
tracking techniques demonstrate the
postsystolic shortening that suggests
abnormal myocardial regional defor-
mation as a response of chronic pressure
overload in early-onset FGR.74 Taking all
together, we believe that fetal echocar-
diography identifies a high-risk group
within the FGR fetuses who could be
targeted for early screening of blood
pressure and other cardiovascular risk
factors later in life and for promoting
healthy diet and physical exercise.58
Finally, biomarkers of cardiac dysfunc-
tion like B-type natriuretic peptide66,71
and markers that reflect cardiac injury,
such as troponin,69,75 are increased in
the cord blood of growth-restricted fe-
tuses in both early and late-onset FGR in
a severity-dependent manner.63,67
Postnatal persistence of cardiovascular
remodeling associated to FGR
Echocardiography in FGR neonates re-
veals similar changes to those in fetuses
that include cardiac morphometry (eg,
dilated left atria and interventricular
septal hypertrophy), diastolic (reduced
absolute E and A wave velocities, higher
E/A ratio, and prolonged isovolumic
relaxation time), and systolic function
(reduced contractility and cardiac
output).69-71 Likewise, other studies re-
ported impaired global longitudinal
strain and regional asynchrony at 2e5
days of life,76 systolic and diastolic car-
diac dysfunction77, and increased cord
blood serum concentrations of B-type
natriuretic peptide.78 Regarding vascular
changes, FGR neonates have increased
blood pressure,79 arterial stiffness,79-81
and aortic intimaemedia thickness
(IMT), which is a marker of preclinical
atherosclerosis.82,83
Cardiovascular changes associated to
FGR persist also into childhood
(Figure 2). Remarkably, both early- and
late-onset forms of FGR and SGA are
associated with cardiac remodeling.
Children with both, early and late-onset
FGR, have more globular hearts,
reduced longitudinal motion, and
impaired relaxation in early and late
childhood.57 Children with milder late-
onset FGR show reduced longitudinal
motion, apparently compensated by
increased radial function, although early-
severe FGR cases fail to show the
compensatory increase in radial motion,
which leads to reduced stroke volume
accompanied by a compensatory increase
in heart rate to maintain cardiac
output.56,57 Significant vascular changes
have also been reported that include
microvascular endothelial dysfunction
and increased blood pressure and
IMT.56,57,84 Furthermore, autopsy studies
of children 1e13 years old demonstrated
atherosclerotic lesions in the aorta, which
is associated inversely with birthweight.85
A recent study reported persistence of
FGR-associated cardiac remodeling until
preadolescence (8e12 years old), with
more spherical ventricles, reduced
longitudinal motion, and impaired
relaxation.86 Literature on vascular
structure and function in adolescents
and young adults with FGR is contro-
versial. A Swedish cohort showed smaller
aortic dimensions in young adults born
with severe FGR.87,88 Two large cohorts
recently have found no association with
arterial wall thickening (IMT) at 11e19
years old.89,90 Large population studies
seem to confirm a significant inverse
correlation between low birthweight and
blood pressure in people of all ages.91
However, this association is of little
magnitude (an increase of 1e4 mmHg),
which could explain the absence of
significant differences in small sample
sizes.
CVD in adults born with FGR
Aside from retrospective epidemiologic
evidence, there are very few prospective
studies in former low birthweight adults.
The Cardiovascular Risk in Young Finns
study was initiated in 1980 and enrolled
3596 children and adolescents aged
3e18 years.92 At an average of 31 years
old, those children born SGA (<10th
percentile) had markedly greater tri-
glycerides, low density lipoprotein
cholesterol, systolic blood pressure, and
IMT compared with controls.93 In the
most recent follow-up evaluation
(34e49 years), there were subtle differ-
ences in heart size and lower left ven-
tricular stroke volume, with normal
ventricular sphericity indices, diastolic
function, and blood pressure in SGA at
term.94 The Enigma study, a long-term
follow-up study of 882 young in-
dividuals from the United Kingdom,
reported a small increase in systolic
blood pressure and central pulse pres-
sure in young adults (mean age, 21 years)
born SGA (<9th percentile).95 However,
this association disappeared after
adjustment for body size.95 Similar
findings have been reported in a longi-
tudinal follow-up study from the United
States that described 20-year-old young
adults born with very low birthweight
(<1500 g) between 1977 and 1979.96
Interpretation of these studies is
challenging, taking into account the
multiple influences that occur during the
life of these individuals and the inherent
limitations in the accuracy of obstetric
information. In any event, available data
suggest that, as life progresses, multiple
factors seem to intervene, which as a
whole attenuate the differences observed
in FGR both in utero and during early
life. Whether there are specific sub-
groups where cardiovascular differences
persist or worsen remain open questions
for future research, as briefly discussed
later on this review.
Expert Reviews ajog.org
S870 American Journal of Obstetrics & Gynecology FEBRUARY 2018
Other factors that influence the
developmental origins of CVD
Besides FGR, prematurity is a common
cause of low birthweight. Preterm birth is
also linked to cardiac remodeling
(shorter and smaller ventricles with
increased mass),97 higher blood pressure
later in life98 and insulin resistance.99,100
Furthermore, in a nationwide Swedish
cohort study that included >2.6 million
live births, Carr et al101 have provided the
first evidence that preterm birth increases
the risk of clinical heart failure during
childhood and adolescence. A relevant
finding of The Cardiovascular Risk in
Young Finns study is the discrimination
between birthweight and prematurity in
the susceptibility to CVDs.92 Reduced
fetal growth and preterm birth increased
independently the severity of subclinical
carotid atherosclerosis and reduced
arterial endothelial function in early
adulthood.93 However, this association
was most pronounced in those born
preterm with FGR; for those born pre-
term without FGR, vascular markers did
not differ from controls, which indicated
that impaired fetal growth drives the as-
sociation of preterm birth with poor
vascular health, as opposed to
prematurity per se.93 In addition, a recent
study that included only preterm gesta-
tions (delivered at 30 weeks gestation)
has shown that, 10 days after birth, in-
fants with FGR have higher systolic blood
pressure and maximum aorta intimae
media thickness compared with preterm
AGA infants.102 These studies suggest
that the mechanisms that program
increased cardiovascular risk after pre-
term birth differ from those that
contribute to increased risk in those born
low birthweight but at full term.
Preeclampsia is often associated to
















Hypotheses on the potential influence of prenatal environment on the risk of cardiovascular disease
Epidemiologic evidence that supports the association between fetal growth and cardiovascular risk (upper panel). A hypothesis on the potential
combination of the prenatal effects of fetal growth restriction with cardiovascular health and risk factors during lifetime and the potential influence of
preventive strategies. Calculated from4.
IMT, intima media thickness.
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offspring of preeclamptic pregnancies
have increased blood pressure during
childhood103,104 and higher risk of
stroke later in life.105 A 20-year follow-
up study found that preterm offspring
of hypertensive pregnancies have evi-
dence of endothelial dysfunction and
greater subclinical atherosclerosis. The
authors postulated that abnormal
vascular development in the fetus in
response to the same placenta-related
factors that affect the mother might
represent the underling mechanism.106
Other factors such as maternal
obesity107 and diabetes mellitus108 have
been also postulated as potential factors
that influence fetal metabolic program-
ming and cardiovascular remodeling.
However, the experimental evidence that
supports its role in CVD programming is
limited compared with that with FGR,
and long-term follow-up studies have
discredited the role of some such as
maternal diabetes mellitus.109,110 The
extent of the influence of these other
perinatal factors in the individual sus-
ceptibility to CVD may be established in
response to the intrauterine milieu or
because of genetic variation that de-
termines both general and vascular
development of the fetus.
Biologic Basis for Fetal
Cardiovascular Programming
FGR and cardiac remodeling at organ,
cellular, and subcellular level
The biologic basis for fetal programming
derives from copious evidence from an-
imal experimentation, with the use of
animal models of ligature of the utero-
placental vessels, maternal hypoxia,
reduction in maternal food intake or
protein restriction, and finally, gluco-
corticoid exposure. Adult offspring of
pregnant rats that were subjected to un-
dernutrition develop obesity, hyper-
insulinemia, and hyperleptinemia,111
specifically in the presence of inactivity
and a high-fat diet.112 Animal models of
maternal nutrient deprivation reported
reduced number of cardiomyocytes at
birth,113 increased myocardial interstitial
fibrosis,114 expression changes of profi-
brotic genes and structural cardiovascu-
lar abnormalities,115 and, importantly,
impairment of recovery after myocardial
ischemia in the offspring.116 Cardiac hy-
pertrophy and coronary artery vascular
reactivity is also evident in lambs born to
ewes undernourished during early
gestation.117 Maternal food restriction
also induces reduced glomerular num-
ber118 and structural changes (remodel-
ing) in smooth muscle content of small
and large vessels in neonatal and young
adult rat offspring.119 Studies that mimic
placental insufficiency by reduction of
uteroplacental vasculature have repro-
duced biometric and cardiovascular
changes of human FGR, such as
increased ductus venous pulsatility, more
spherical ventricles, reduced longitudinal
motion, and presence of postsystolic
shortening.120,121
Experimental FGR models have
shown the extensive variety of cellular
and subcellular changes induced by this
condition, which include reduced num-
ber of cardiomyocytes, increased car-
diomyocyte volume, reduction in
myocardium microvascularization,122
shorter sarcomeres, mitochondrial rear-
rangement, and altered gene expression
related to energy and oxygen homeo-
stasis.123,124 Reduced sarcomere length
have also been reported in human
fetuses.125 Other studies that focused on
chronic hypoxia showed changes in fetal
cardiac structure and function,126,127
increased collagen content,128 changes
in cardiomyocyte proliferation and
apoptosis,129 postnatal changes in the
isoforms of proteins that are important
for the sarcomeric structure, including
titin and myosin,130,131 and increased
cardiac susceptibility to ischemia
reperfusion.132,133
Molecular mechanisms of fetal
programming: epigenetics
Epigenetic changes have been postulated
as the most important mechanism
driving fetal programming.134 Individ-
uals prenatally exposed to the Dutch
famine of 1944-45 had, six decades later,
less DNA methylation of the imprinted
insulin growth factor-2 gene compared
with their unexposed, same-sex sib-
lings.135 Clinical studies have reported
that the DNA methylation pattern in
cells from cord blood136,137 and
placenta138 between FGR human
pregnancies and controls is different,
affecting genes involved in metabolism
and adipose tissue differentiation.
Importantly, the phenotypic effects of
epigenetic modifications during devel-
opment may not manifest until later in
life, especially if they affect pathways of
genes that modulate responses to envi-
ronmental challenges, such as a high-fat
diet.139
The influence of the prenatal envi-
ronment in the epigenome has also
been shown in experimental studies. A
caloric-dense maternal diet has the
ability to generate epigenetic effects on
the offspring, altering fetal chromatin
structure in primates.140 Moreover,
maternal undernutrition leads to long-
term cholesterol dysregulation in the
offspring via epigenetic mechanisms,141
modifies gene expression of fetal renal
transcription and growth factors,47 and
can alter permanently the expression of
miRNAs in the aortas of newborn and
aging rat offspring.142 These epigenetic
marks may also be transmitted to
future generations.134,143 This effect
has also been demonstrated in animal
models, showing that fetal adaptations
such as endothelial dysfunction, hy-
pertension, and insulin resistance are
passed to the second and third gener-
ation of undernourished pregnant
rats.144
The relevance of epigenetics in the
adaptation to chronic cardiac failure has
been highlighted in human adults, with
distinct reported signatures of DNA
methylation in cardiac tissue.145,146 A
recent analysis of the DNA methylome
from cardiomyocytes of neonatal
healthy, adult, and adult with failing
heart revealed a dominant role for DNA
methylation as a highly dynamic and
reversible process during cardiomyocyte
development, postnatal maturation, and
disease.147 In fetal life, treatment of
pregnant rats with hypoxia leads to DNA
hypermethylation that has been associ-
ated with early transition frommono- to
binucleate cardiomyocyte, which re-
duces the number of cardiomyocytes
in the developing heart,148 and an
increase in the susceptibility to ischemic
injury in the offspring.149 These con-
siderations point to epigenetic processes
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that play a key role in the developmental
origins of CVD.
Clinical Implications, Open
Questions, and Opportunities for
Research
The evidence summarized herein sup-
ports that FGR induces cardiovascular
programming and remodeling, and that
it is plausible that these changes pose an
increased risk for CVD later in life.
However, whether and how other factors
that appear later in life interact with this
predisposition to evolve to clinical CVD
remains a subject of research. The “sec-
ond hit” hypothesis, which is well
accepted in fields such as human
oncology, postulates that a genetic/
epigenetic predisposition requires a sec-
ond insult to manifest as clinical dis-
ease. Therefore, it is not unreasonable
to postulate that cardiovascular sub-
clinical remodeling in growth-restricted
fetuses entails a higher predisposition,
which needs to be combined with
other factors to evolve to clinically
relevant disease. And hence, some of
the structural and functional changes
that result from fetal programming
could be corrected or further deviated,
depending on other events or expo-
sures during life.
In combination with this idea, a sec-
ond important aspect that needs to be
addressed by future research is the exis-
tence of windows of opportunity
(Figure 2). As shown in animal models,
changes in metabolism or epigenetic
patterns that are determined by prenatal
exposure are correctable if the inter-
vention is introduced very early in life,
but not later.150-153 Regardless of
whether there is a well-defined period, a
“window of opportunity” that “closes”
later in life, or just a steady decline of
the opportunity for correction as the
individual matures, evidence suggests
that early life interventions can have
strong effects on the cardiovascular
changes that are associated with FGR.
Key putative early life intervention stra-
tegies that may improve or restore
vascular and cardiac health in a child-
hood that was affected by FGR include
maintenance of healthy weight, promo-
tion of breastfeeding,154 and dietary
interventions.155,156 Observational and
in-vivo studies indicate that breastfeed-
ing and consumption of a diet with a
high polyunsaturated:saturated fat ratio
in early childhood improves cardio-
vascular remodeling in individuals
born with FGR.37,154 Similarly, dietary
consumption of either marine (eicosa-
pentaenoic acid) and docosahexaenoic
acid or plant-derived (a-linolenic acid)
omega-3 fatty acids appear to have
specific hemodynamic and vascular
benefits in children and adolescents
who were born SGA, but not in chil-
dren who were born with normal
birthweight.90,156,157
Therefore, important challenges for
future research are to ascertain the
mechanistic pathways whereby fetal
cardiovascular programming might
lead to CVD in adulthood. Although it
is likely that, as a whole, the effects of
FGR on adult cardiovascular mortality
rate are not huge, the identification of
specific subgroups at higher risk, and
especially the characterization of life-
style factors that promote accelerated
progression to CVD disease in subjects
who experienced FGR, could have a
strong influence on their quality of life.
Considering that FGR affects a large
share of the population, the possibility
of reducing morbidity in only a frac-
tion of these patients could be
remarkable.
In summary, FGR has a strong influ-
ence in cardiovascular health, opening
opportunities to improve public health
by the identification of perinatal factors
that can determine strongly the in-
dividual’s health and potentially accel-
erate the implementation of preventive
strategies starting from fetal or early
postnatal life. -
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